Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03916406 | THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS | PHASE1 | COMPLETED | 10 | — | — | Apr 18, 2019 | Jun 25, 2019 | Jul 16, 2019 | 1 | Belgium |
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | midazolam alone followed by combination of PF 06835919 and midazolam |
| Sequence 2 | EXPERIMENTAL | PF 06835919 in combination with midazolam followed by midazolam alone |
| Name | Type | Description |
|---|---|---|
| PF 06835919 | DRUG | 300 mg |
| Midazolam | DRUG | 7.5 mg |
Inclusion Criteria: * Male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiovascular tests. * Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). Exclusion Cri...